FDA approved AD drugs such as acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate receptor antagonists only alleviate symptoms in about half of the patients for approximately 6–12 months (Winslow et al., 2011). Here, ACHE is linked to Alzheimer disease.